Plain-English translation of NCT07587515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called for patients with wet age-related macular degeneration, a serious eye condition that damages central vision. The medication is delivered directly into the eye as an injection every 6 months. Researchers want to determine whether the treatment is safe, how it behaves in your body, and whether it helps slow or stop vision loss.
Wet age-related macular degeneration can lead to significant vision loss and blindness if left untreated. Current treatments require frequent eye injections, and this trial is exploring whether this new medication could be given less often while still protecting your vision.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the study medication directly into your eye every 24 weeks (about 6 months). Throughout the trial, you would attend multiple clinic visits where researchers will check your eye health, take imaging scans, and monitor how you are responding to the treatment. The study will last several months, and you'll be closely monitored to make sure the medication is safe and working as expected.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States